Enliven Therapeutics (ELVN) Return on Capital Employed Growth (1y) (2021 - 2026)
Enliven Therapeutics (ELVN) Return on Capital Employed Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | 1,648.00 |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 31,429.00 |
| 4 | BeOne Medicines | 472.75 Bn | 467.96 Bn | 1.35 Bn | 1,805.00 |
| 5 | Vertex Pharmaceuticals | 122.14 Bn | 114.89 Bn | 2.59 Bn | 2,503.00 |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | -105.00 |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 2,400.00 |
| 10 | Enliven Therapeutics | 3.38 Bn | 2.93 Bn | - | 1,150.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1,150.00 |
| Dec 31, 2025 | 926.00 |
| Sep 30, 2025 | 1,029.00 |
| Jun 30, 2025 | 175.00 |
| Mar 31, 2025 | -375.00 |
| Dec 31, 2024 | -108.00 |
| Sep 30, 2024 | -719.00 |
| Jun 30, 2024 | -1,107.00 |
| Mar 31, 2024 | -743.00 |
| Dec 31, 2023 | 2,928.00 |
| Sep 30, 2023 | 4,516.00 |
| Jun 30, 2023 | 4,530.00 |
| Mar 31, 2023 | 3,644.00 |
| Dec 31, 2022 | -785.00 |
| Sep 30, 2022 | -1,259.00 |
| Jun 30, 2022 | 232.00 |
| Mar 31, 2022 | -673.00 |
| Dec 31, 2021 | -852.00 |
| Sep 30, 2021 | -2,147.00 |
| Jun 30, 2021 | -3,753.00 |